GlassScriptPhysician profile
Alka Nair
NPI 1033256326
$4,606.65
in general payments reported to CMS, 2019-2025
36 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $240 · 2021: $139 · 2022: $490 · 2023: $1,035 · 2024: $1,284 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,222 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,221.67 |
| Education | $108.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $934.47 | 2020-2025 | |
| Amgen INC. | $600.25 | 2019-2025 | Evenity, Krystexxa, Otezla |
| Pfizer INC. | $414.58 | 2019-2025 | |
| Janssen Biotech, INC. | $349.07 | 2020-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $301.07 | 2024-2025 | |
| Lilly USA, LLC | $264.88 | 2022-2024 | Taltz, Mounjaro, Zepbound |
| Exact Sciences Corporation | $250.00 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $197.88 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Medtronic Vascular, INC. | $145.34 | 2019 | |
| Astellas Pharma US INC | $133.84 | 2019-2024 | Veozah |
| Ucb, INC. | $107.22 | 2021-2025 | Bimzelx, Cimzia |
| Actelion Pharmaceuticals US, INC. | $105.50 | 2023-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.89 | 2019-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $72.88 | 2019-2024 | Airsupra |
| Allergan, INC. | $67.51 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $64.06 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $58.52 | 2023 | Xarelto |
| Sobi, INC | $54.64 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $35.84 | 2023 | Lupkynis |
| Biohaven Pharmaceutical Holding Company LTD. | $35.62 | 2022 | |
| Insmed, INC. | $34.83 | 2025 | Arikayce |
| Antares Pharma, INC. | $29.29 | 2020 | |
| Merck Sharp & Dohme LLC | $25.32 | 2019-2025 | Capvaxive, Gardasil 9 |
| E.R. Squibb & Sons, L.L.C. | $23.85 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $21.24 | 2019 | |
| Mallinckrodt Hospital Products INC. | $21.19 | 2024 | Acthar |
| Kiniksa Pharmaceuticals, LTD. | $19.92 | 2023 | Arcalyst |
| Horizon Therapeutics Plc | $19.82 | 2023 | Krystexxa |
| Sanofi Pasteur INC. | $19.64 | 2019 | |
| Phathom Pharmaceuticals, INC. | $18.47 | 2024 | Voquezna |
| Novo Nordisk INC | $18.15 | 2024 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $18.05 | 2020 | |
| Fresenius Kabi USA, LLC | $17.52 | 2023 | |
| Ani Pharmaceuticals, INC. | $17.18 | 2022 | |
| Radius Health, INC. | $14.32 | 2023 | Tymlos |
| Circassia INC. | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alka Nair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.